Galecto

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

stock-market-6693060

News

GLTO

Galecto shares are trading lower by 27% during Monday&#39;s session. The company issued 62,594 common and 160,562 preferred convertible shares to Bridge Medicine for BRM-1420 acquisition rights.

Why Galecto (GLTO) Shares Are Down 27% Today

Earnings

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

RKLB

With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:

Nike, AAR And 3 Stocks To Watch Heading Into Friday

Small Cap

Intraday Update

Movers

ADES

AONC

APLS

AVGR

AXLA

BHVN

COOK

CRDF

FEMY

FENG

FFIE

IMVT

INPX

LIFW

MCLD

METC

MLKN

PIXY

PYPD

RNAZ

SLNO

SOUN

SPRC

STSS

THAR

UTRS

VBIV

VINO

XWEL

Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Galecto Inc

6 Stocks Positioned to Soar as Investors Focus on MASH

Press Releases

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

Galecto Announces Reverse Stock Split

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

Management

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

Galecto Reports Third Quarter 2024 Financial Results

Galecto to Participate in Upcoming Investor Conferences

AKRO

BIXT

CANF

ETNB

GALT

MDGL

VKTX

Aditxt

Ainos

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Alzamend Neuro

Aptevo Therapeutics

Azitra

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Carmell

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Ensysce Biosciences

GT Biopharma

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Mustang Bio

Moleculin Biotech

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Sunshine Biopharma

SILO Pharma

Soligenix

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Xenetic Biosciences

Oppenheimer

SVB Leerink

Cantor Fitzgerald

Credit Suisse

Comments

Galecto

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga